Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Equivalents (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Cash & Equivalents data on record, last reported at $228.1 million in Q2 2025.

  • For Q2 2025, Cash & Equivalents fell 2.2% year-over-year to $228.1 million; the TTM value through Jun 2025 reached $228.1 million, down 2.2%, while the annual FY2024 figure was $222.5 million, 22.29% down from the prior year.
  • Cash & Equivalents reached $228.1 million in Q2 2025 per MIRM's latest filing, up from $222.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $303.1 million in Q3 2023 and bottomed at $46.3 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $197.0 million, with a median of $223.0 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: tumbled 48.97% in 2022, then soared 512.81% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $131.3 million in 2021, then fell by 2.54% to $128.0 million in 2022, then soared by 123.69% to $286.3 million in 2023, then dropped by 22.29% to $222.5 million in 2024, then grew by 2.53% to $228.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $228.1 million in Q2 2025, $222.5 million in Q4 2024, and $223.0 million in Q3 2024.